Rini, B. I., Tannir, N. M., Escudier, B., McDermott, D. F., Grimm, M. O., Porta, C., … George, S. (2018). Characterization of response to nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (Pts) with previously untreated advanced renal cell carcinoma (arcc): Checkmate 214. Annals of Oncology : Official Journal of the European Society for Medical Oncology, 29, viii309–viii310. https://doi.org/10.1093/annonc/mdy283.084

Rini, B. I., N. M. Tannir, B. Escudier, D. F. McDermott, M. O. Grimm, C. Porta, T. Powles, et al. “Characterization of response to nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (Pts) with previously untreated advanced renal cell carcinoma (arcc): Checkmate 214.” Annals of Oncology : Official Journal of the European Society for Medical Oncology 29 (October 1, 2018): viii309–10. https://doi.org/10.1093/annonc/mdy283.084.

Rini BI, Tannir NM, Escudier B, McDermott DF, Grimm MO, Porta C, et al. Characterization of response to nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (Pts) with previously untreated advanced renal cell carcinoma (arcc): Checkmate 214. Annals of oncology : official journal of the European Society for Medical Oncology. 2018 Oct 1;29:viii309–10.

Rini, B. I., et al. “Characterization of response to nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (Pts) with previously untreated advanced renal cell carcinoma (arcc): Checkmate 214.” Annals of Oncology : Official Journal of the European Society for Medical Oncology, vol. 29, Oct. 2018, pp. viii309–10. Scopus, doi:10.1093/annonc/mdy283.084.

Rini BI, Tannir NM, Escudier B, McDermott DF, Grimm MO, Porta C, Powles T, Kollmannsberger CK, Gurney HP, Tykodi SS, Harrison M, Heng DYC, Grünwald V, Choueiri TK, Mekan S, McHenry MB, Hammers HJ, Motzer RJ, George S. Characterization of response to nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (Pts) with previously untreated advanced renal cell carcinoma (arcc): Checkmate 214. Annals of oncology : official journal of the European Society for Medical Oncology. 2018 Oct 1;29:viii309–viii310.